{"id":3201,"date":"2018-09-19T15:51:37","date_gmt":"2018-09-19T10:21:37","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3201"},"modified":"2021-07-24T12:57:04","modified_gmt":"2021-07-24T07:27:04","slug":"snippet-7","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/snippet-7","title":{"rendered":"Snippet"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Novo Nordisk set to restructure R&amp;D business <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Novo Nordisk<\/strong>, Danish drug maker, declared its plans to <strong>reorganise<\/strong> their <strong>R&amp;D business<\/strong>, which include lay-off 400 workers of operations in Denmark and China. It is done so that the expansion is accelerated and its pipeline across serious <a href=\"https:\/\/www.delveinsight.com\/report-store\/b-cell-chronic-lymphocytic-leukemia-market\">chronic diseases<\/a> is diversified. \u00a0Novo ruminates to have four &#8220;Transformational Research Units&#8221; in place that will be concentrated on finding new therapies and technologies. Also, the drug maker apprised regarding investment that it will be done more in automation, machine learning and artificial intelligence to accelerate drug discovery, laboratory infrastructure and information technology, so to make R&amp;D more efficient.<\/p>\n<p style=\"text-align: justify;\">\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk set to restructure R&amp;D business Novo Nordisk, Danish drug maker, declared its plans to reorganise their R&amp;D business, which include lay-off 400 workers of operations in Denmark and China. It is done so that the expansion is accelerated and its pipeline across serious chronic diseases is diversified. \u00a0Novo ruminates to have four &#8220;Transformational [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3110,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[1837,1838,1840,1833,1839,877,1834,1835,1836],"industry":[17225],"therapeutic_areas":[17233,17228,17234],"class_list":["post-3201","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-artificial-intelligence","tag-automation","tag-drug-discovery","tag-drug-maker","tag-machine-learning","tag-novo-nordisk","tag-rd-business","tag-serious-chronic-diseases","tag-transformational-research-units","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Snippet| Novo Nordisk - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"Novo Nordisk, Danish drug maker, declared its plans to reorganise their R&amp;D business, which include lay-off 400 workers of operations in Denmark....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/snippet-7\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snippet| Novo Nordisk - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk, Danish drug maker, declared its plans to reorganise their R&amp;D business, which include lay-off 400 workers of operations in Denmark....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/snippet-7\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-19T10:21:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021353\/1_D6PxtJRLHGC-n_vK9nUuKg-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"453\" \/>\n\t<meta property=\"og:image:height\" content=\"338\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Snippet| Novo Nordisk - DelveInsight Business Research LLP","description":"Novo Nordisk, Danish drug maker, declared its plans to reorganise their R&D business, which include lay-off 400 workers of operations in Denmark....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/snippet-7","og_locale":"en_US","og_type":"article","og_title":"Snippet| Novo Nordisk - DelveInsight Business Research LLP","og_description":"Novo Nordisk, Danish drug maker, declared its plans to reorganise their R&D business, which include lay-off 400 workers of operations in Denmark....","og_url":"https:\/\/www.delveinsight.com\/blog\/snippet-7","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-09-19T10:21:37+00:00","article_modified_time":"2021-07-24T07:27:04+00:00","og_image":[{"width":453,"height":338,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021353\/1_D6PxtJRLHGC-n_vK9nUuKg-1.jpeg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-7","url":"https:\/\/www.delveinsight.com\/blog\/snippet-7","name":"Snippet| Novo Nordisk - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-7#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-7#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021353\/1_D6PxtJRLHGC-n_vK9nUuKg-1.jpeg","datePublished":"2018-09-19T10:21:37+00:00","dateModified":"2021-07-24T07:27:04+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Novo Nordisk, Danish drug maker, declared its plans to reorganise their R&D business, which include lay-off 400 workers of operations in Denmark....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/snippet-7"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-7#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021353\/1_D6PxtJRLHGC-n_vK9nUuKg-1.jpeg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021353\/1_D6PxtJRLHGC-n_vK9nUuKg-1.jpeg","width":453,"height":338,"caption":"Novo Nordisk"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/08\/09021353\/1_D6PxtJRLHGC-n_vK9nUuKg-1-300x224.jpeg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">artificial intelligence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">automation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">drug discovery<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">drug maker<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">machine learning<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Novo Nordisk<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">R&amp;D business<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">serious chronic diseases<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Transformational Research Units<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">artificial intelligence<\/span>","<span class=\"advgb-post-tax-term\">automation<\/span>","<span class=\"advgb-post-tax-term\">drug discovery<\/span>","<span class=\"advgb-post-tax-term\">drug maker<\/span>","<span class=\"advgb-post-tax-term\">machine learning<\/span>","<span class=\"advgb-post-tax-term\">Novo Nordisk<\/span>","<span class=\"advgb-post-tax-term\">R&amp;D business<\/span>","<span class=\"advgb-post-tax-term\">serious chronic diseases<\/span>","<span class=\"advgb-post-tax-term\">Transformational Research Units<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 19, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 19, 2018 3:51 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3201"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3201\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3110"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3201"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3201"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}